Inflammatory Intestinal Diseases最新文献

{"title":"Pharmacologic treatment of eosinophilic esophagitis: efficacious, likely efficacious, and failed drugs","authors":"A. Schoepfer, Ekaterina Safroneeva","doi":"10.1159/000540275","DOIUrl":"https://doi.org/10.1159/000540275","url":null,"abstract":"Background: Treatment options for Eosinophilic esophagitis (EoE) evolve rapidly. This review focuses on pharmacologic options to treat EoE. \u0000Summary: Orodisopersible budenoside tablets (Jorveza®) have been approved by regulatory authorities for EoE treatment of adults in Europe, Canada and Australia, but not the United States. Jorveza®, as compared to placebo, is effective in inducing and maintaining histologic and clinical remission over time. Before the approval of Jorveza®, several investigator-initiated randomized controlled clinical studies evaluated esophagus-targeted formulations of either budesonide or fluticasone to treat pediatric and adult EoE patients. These drugs were generally efficacious in inducing and maintaining histological and clinical remission. Proton-pump inhibitors (PPI) are used off-label for EoE treatment of pediatric and adult EoE patients given that they are able to induce histologic and clinical remission. Dupilumab (Dupixent®), a monoclonal antibody targeted against IL-4 and IL-13, was approved by regulatory authorities in the United States, Europe, Canada, but not yet Australia. In Europe, including Switzerland, Dupixent® is approved to treat EoE patients of at least 12 years of age with at least 40 kg body weight if they are either unresponsive or intolerant to or not candidates for conventional EoE therapies. Due to lack of efficacy or unfavorable safety profile, the following drugs are not recommended for EoE treatment: systemic steroids, sodium cromoglycate, montelukast, azathioprine, TNF-antagonists (eg. infliximab), vedolizumab (mAb against α4β7), benralizumab (mAb against IL-5 receptor), mepolizumab (mAb against IL-5), reslizumab (mAb against IL-5), omalizumab (mAb against IgE), and lirentelimab (mAb against siglec-8). \u0000Key messages: Long-term effectiveness and safety data on different drugs are currently sparse. Concerted efforts of different stakeholders will be necessary to continue the endeavour of providing our patients with much-needed therapies.\u0000","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141799529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of Pharmacist-Led Medication Guidance for Patients with Inflammatory Bowel Disease in Japan","authors":"Kuninori Iwayama, Kazuya Hiura, K. Ohtaki","doi":"10.1159/000540558","DOIUrl":"https://doi.org/10.1159/000540558","url":null,"abstract":"Introduction: In pharmacotherapy for inflammatory bowel disease (IBD), good medication adherence is necessary to control the condition. However, some patients show poor adherence. Pharmacists need to provide appropriate medication guidance to improve medication adherence. Community pharmacists often have to provide medication guidance in case of insufficient patient information because of varying affiliations. Therefore, to help improve medication adherence in patients with IBD and establish cooperation between community and hospital pharmacies, we investigated the awareness of IBD among pharmacists and the actual status of pharmacist-led medication guidance for patients with IBD.\u0000Methods: This study comprised a knowledge test for IBD and a survey of medication guidance for IBD in the form of questionnaires, which were administered to pharmacists using web forms.\u0000Results: Community pharmacy affiliation (P < 0.01) and having no experience in medication guidance for IBD (P < 0.01) contributed to low scores in the IBD knowledge test. There was a difference in the correct answer rate for interactions or screening tests prior to medication administration between community and hospital pharmacists. Medication guidance consultations involving residual drug adjustment (P < 0.01), confirmation of symptoms (P < 0.01), prescription from other hospitals (P = 0.04), therapeutic effects (P = 0.04), and confirmation of medication adherence were more common among community pharmacists than among hospital pharmacists. Cooperation between community and hospital pharmacies was most commonly achieved through tracing reports or personal medication handbooks.\u0000Conclusion: Improving pharmacists’ awareness of IBD and sharing information is important to facilitate cooperation between community and hospital pharmacists to improve medication adherence.","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141805077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients' Preference on Advanced Therapy and Follow-Up Procedure for Inflammatory Bowel Disease in Japan: A Web-Based 3A Survey.","authors":"Toshifumi Morishita, Shunichi Yanai, Yosuke Toya, Takayuki Matsumoto","doi":"10.1159/000539738","DOIUrl":"10.1159/000539738","url":null,"abstract":"<p><strong>Introduction: </strong>With the recent increase in number of drugs for treating inflammatory bowel disease (IBD), it has become important to select treatments acceptable to patients. Endoscopy and biomarkers from blood and stool samples are used to evaluate IBD disease activity. This study aimed to clarify the acceptability of usage of advanced therapy and examination methods in patients through an internet-based survey.</p><p><strong>Methods: </strong>Patients with inflammatory bowel disease were asked via the internet to participate in a survey on the acceptability of nine therapies and three examination methods. The respondents rated acceptability on a scale of 1-10 and specified the most preferred option.</p><p><strong>Results: </strong>Responses were obtained from 388 patients with ulcerative colitis and 82 with Crohn's disease; 14.5% and 11.5% of the patients underwent intravenous infusions and subcutaneous injections, respectively. Once-daily oral administration had the highest acceptability score, which was significantly different from other administration usages (<i>p</i> < 0.0001), regardless of prior treatment history. Oral administration was preferred by 88.9% of patients. The ranking of examination methods from most to least acceptable was blood tests > endoscopy > stool tests, with significant differences among all groups (<i>p</i> < 0.0001). Blood testing (76%) and stool testing (4.5%) were the most and least preferred methods, respectively.</p><p><strong>Conclusions: </strong>The most acceptable usage of advanced therapy in patients with inflammatory bowel disease was once-daily oral administration. Treatments that are effective, safe, and acceptable to patients should be selected, and examination methods acceptable to patients should be used.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cohort Profile Update: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).","authors":"Jeanine Wakim El-Khoury, Ekaterina Safroneeva, Catherine Saner, Jean-Benoit Rossel, Sven Trelle, Marcel Zwahlen, Luc Biedermann, Andrea Kreienbuehl, Thomas Greuter, Philipp Schreiner, Peter Netzer, Annett Franke, Stephan Brand, Chantal Hasler, Patrick Aepli, Emanuel Burri, Achim Weber, Christine Sempoux, Ruggero Biral, Wolfram Jochum, Joachim Diebold, Niels Willi, Alex Straumann, Alain M Schoepfer","doi":"10.1159/000539713","DOIUrl":"10.1159/000539713","url":null,"abstract":"<p><strong>Introduction: </strong>The Swiss Eosinophilic Esophagitis Cohort Study (SEECS) is a national cohort that was established in 2015 with the aim of improving quality of care of affected adults with eosinophilic esophagitis (EoE). Between 2020 and 2022, paper questionnaires were gradually replaced by fully electronic data capture using Research Electronic Data Capture (REDCap^®) software. We aim to provide an update of the SEECS 8 years after its launch.</p><p><strong>Methods: </strong>The SEECS prospectively includes adults (≥18 years of age) with EoE as well as patients with gastroesophageal reflux disease (GERD) and healthy control subjects (HC). Upon inclusion and follow-up (typically once every 12-18 months), patients and physicians complete REDCap^® questionnaires, which are available in German, French, and English. Patient-reported outcomes (PROs) and biologic findings are assessed on the same day using validated instruments (EEsAI PRO for symptoms; EoE-QoL-A for QoL; EREFS for endoscopic activity; modified EoE-HSS for histologic activity). The SEECS biobank includes biosamples from patients with EoE, GERD, and HC.</p><p><strong>Results: </strong>As of July 2023, the SEECS included 778 patients (716 [92%] with EoE, 29 [3.8%] with GERD, and 33 [4.2%] HC; 559/778 [71.9%] were male). Mean age ± SD (years) at enrollment according to diagnosis was as follows: EoE 41.9 ± 12.9, GERD 53.6 ± 16.4, HC 51.7 ± 17.2. Concomitant GERD was found in 200 patients (27.9%) of the EoE cohort. Concomitant allergic disorders (asthma, rhinoconjunctivitis, eczema) were present in 500 EoE patients (74.4%). At inclusion, 686 (95.8%) of EoE patients were on ongoing treatment (orodispersible budesonide tablet [Jorveza^®] in 281 patients [41%]; budesonide or fluticasone syrup or swallowed powder in 290 patients [42.3%]; proton-pump inhibitors in 162 patients [23.6%]; elimination diets in 103 patients [15%]; and esophageal dilation at last visit in 166 patients [24.2%]). A total of 8,698 biosamples were collected, of which 1,395 (16%) were used in the framework of translational research projects.</p><p><strong>Conclusion: </strong>SEECS continuously grows and is operational using fully electronic data capture. SEECS offers up-to-date epidemiologic and real-world clinical efficacy data on EoE and promotes clinical and translational research.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Treatment for Children and Adults with Eosinophilic Esophagitis: Which Patient and Which Doctor Is It Suitable for?","authors":"Javier Chahuan, Alfredo J Lucendo","doi":"10.1159/000540228","DOIUrl":"10.1159/000540228","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of dietary therapy to induce remission of eosinophilic esophagitis (EoE) has been evaluated over the last decades and summarized in meta-analyses. Choosing the dietary modality, identifying the most suitable patients, and implementing specific prerequisites are essential to ensure long-term success.</p><p><strong>Summary: </strong>Impractical exclusive elemental diets provided the highest remission rates in EoE; however, they are not recommended due to their numerous disadvantages and detrimental effects on patient quality of life. Allergy testing-guided diets for EoE are limited; their insufficient effectiveness and low reproducibility are due to poor accuracy of skin or serum test results in identifying EoE food triggers. Initial experiences with a six-food elimination diet have provided evidence of high and predictive effectiveness rates and paved the way for less restrictive and more efficient step-up approaches, including four-food, two-food, and most recently, milk elimination diets. Dietary treatment for EoE is challenging for patients and families and requires certain skills to ensure success in the short and long term.</p><p><strong>Key messages: </strong>The selection of appropriate patients is essential to ensure the success of and long-term adherence to dietary treatment of EoE. As normal triggers for EoE are commonly found in the staple diet, it is important to ensure adequate nutritional substitutes to avoid nutrient deficiency risks when long-lasting feeding difficulties or extensive restrictions are present. Specialized facilities in dietary therapy should adopt patient-centered and personalized approaches in order to provide timely monitoring and support for complex cases.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What happens to patients with inflammatory bowel disease who are intolerant to thiopurines?","authors":"H. Gensmyr-Singer, P. Karling","doi":"10.1159/000539287","DOIUrl":"https://doi.org/10.1159/000539287","url":null,"abstract":"Introduction: The clinical consequences for patients with inflammatory bowel disease (IBD) who stop treatment owing to side effects have not been fully investigated.\u0000Methods: This retrospective observational study aimed to compare patients who discontinued thiopurine treatment due to side effects with those who tolerated thiopurine treatment in the use of other IBD drugs, surgery, and fecal calprotectin values in the first five years after the start of thiopurine treatment. \u0000Results: The proportion of patients with IBD who initiated thiopurine treatment at our clinic was 44% (32% ulcerative colitis and 64% Crohn´s disease) and 31% (n=94) of those patients had to stop thiopurine treatment within five years due to side effects. Patients who discontinued thiopurine treatment due to intolerance were significantly older (median age 33 vs 27 years, p=0.003), significantly more often used prednisolone (89% vs. 76%, p=0.009) and used to a lesser extent TNF-inhibitors at the start of thiopurine treatment (3% vs. 9%, p=0.062). Budesonide treatment and non-TNF-inhibitor second-line therapy were significantly more commonly used in patients who discontinued thiopurine treatment owing to side effects, but there were no statistically significant differences in the use of other treatments. The proportion of patients with a median FC >200 g/g was significantly higher during follow-up in patients with UC who discontinued thiopurine treatment owing to side effects.\u0000Conclusions: Patients who discontinued thiopurines owing to side effects were prescribed more budesonide and non-TNF inhibitor second-line therapy, but there were no differences in the use of TNF-inhibitors, prednisolone, or surgery. \u0000","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141360712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenteric Panniculitis.","authors":"Cecilio Azar, Mohamad Ali Ibrahim, Zakaria El Kouzi, Ali El Mokahal, Nadine Omran, Nadim Muallem, Ala I Sharara","doi":"10.1159/000539432","DOIUrl":"10.1159/000539432","url":null,"abstract":"<p><strong>Background: </strong>Mesenteric panniculitis (MP) is an uncommon non-neoplastic idiopathic inflammation of adipose tissue, mainly affecting the mesentery of the small intestine, with its etiology remaining largely speculative. The difference in prevalence of MP among females and males varies across multiple studies. In most cases, MP is asymptomatic; however, patients can present with nonspecific abdominal symptoms or can mimic underlying gastrointestinal and abdominal diseases. The diagnosis is suggested by computed tomography and is usually confirmed by surgical biopsies if necessary. Treatment is generally supportive and based on a few selected drugs, namely, nonsteroidal anti-inflammatory drugs or corticosteroids. Surgery is reserved when the diagnosis is unclear, when malignancy is suspected or in the case of severe presentation such as mass effect, bowel obstruction, or ischemic changes.</p><p><strong>Summary: </strong>MP is a rare inflammatory condition of the mesentery often asymptomatic but can cause nonspecific abdominal symptoms. Diagnosis relies on computed tomography imaging, with treatment mainly supportive, utilizing medications like nonsteroidal anti-inflammatory drugs or corticosteroids, while surgery is reserved for severe cases or diagnostic uncertainty.</p><p><strong>Key messages: </strong>MP causes abdominal pain, and it is mainly diagnosed with CT scan.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of magnetic resonance enterography and double balloon enteroscopy-assisted endoscopic balloon dilatation for small bowel strictures in Crohn’s disease: A retrospective observational study","authors":"Arteen Arzivian, Ahmad Alrubaie, Jessica Yang, Huiyu Lin, Eva Zhang, Rupert Leong","doi":"10.1159/000539401","DOIUrl":"https://doi.org/10.1159/000539401","url":null,"abstract":"Introduction: Crohn’s disease (CD) of the small bowel is associated with a severe course and increased risk of complications. Strictures at this location are challenging to diagnose and out-of-reach of colonoscopy. We aimed to evaluate the detection rate of small bowel strictures with magnetic resonance enterography (MRE) and assess the efficacy of double-balloon enteroscopy-assisted endoscopic balloon dilatation (DBE-assisted EBD) in managing these strictures.\u0000Methods: A retrospective study included all patients with DBE-assisted EBD of small bowel strictures in CD in our facility. All patients had MRE to detect strictures prior to the dilatation. Sequential dilatation protocol was performed using through-the-scope (TTS) working channel balloons. The outcomes included technical success defined by the passage of the enteroscope post-dilatation, resolution of symptoms and the requirement of repeated procedures or surgery during 12 months of follow-up.\u0000Results: 20 DBE-assisted EBDs of small bowel strictures were attempted during 13 DBE procedures in 10 patients (6 males, median age 42). MRE identified 75% of the strictures with 100% accuracy in localisation. Retrograde DBE was the approach in 16/20 (80%) strictures. Anesthetic intubation was used in 8/20 (40%). DBE reached 19/20 strictures. All the reached strictures were dilated successfully; the technical success following dilatation was 72.2%. The median DBE insertion time with TTS balloon dilatation was 66 minutes. Three patients required follow-up dilatations within 2-3 months. Surgery was not needed during the follow-up period. \u0000Conclusions: MRE is essential in diagnosing and localising small bowel strictures in CD. DBE reached 95% of strictures with successful dilatation. Immediate technical success was high, and safety was demonstrated. Planned repeat procedures for sequential dilatation were performed in a few patients. Surgical resection was avoided in all patients.","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141122887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of an E-Learning Educational Program for Acquiring Basic Knowledge in Inflammatory Bowel Disease Nursing.","authors":"Hikaru Mizuno, Yu Fujimoto, Yoshiko Furukawa, Mayu Katashima, Koji Yamamoto, Kayoko Sakagami, Maya Nunotani, Natsuko Seto","doi":"10.1159/000539005","DOIUrl":"10.1159/000539005","url":null,"abstract":"<p><strong>Introduction: </strong>This study focuses on developing and validating an e-learning educational program for nurturing inflammatory bowel disease (IBD) nursing specialists.</p><p><strong>Methods: </strong>The program was developed using the attention, relevance, confidence, and satisfaction models within the instructional design framework. The program validation encompassed four steps: (1) nurses took a basic IBD knowledge test (pretest), (2) participants scoring <80% were encouraged to undergo web-based training, (3) a follow-up test (posttest) gauged post-training improvement, and (4) participant satisfaction with e-learning was assessed.</p><p><strong>Results: </strong>The analysis included 63 participants. The average score in the pretest was 81.3%, 40 participants exceeded the pretest passing score, which is 80% (average: 88.3%), and 23 participants failed (average: 69.1%). Of those who failed, 19 participants showed improvement after undergoing web-based training, with their posttest scores exceeding the passing threshold (average: 97.4%). The comparison results between the passing and failing groups revealed no correlation between the baseline characteristics of the participants. The participants were highly satisfied with the e-learning program.</p><p><strong>Conclusion: </strong>The program was effective as an educational program for acquiring basic knowledge to foster IBD nursing professionals. The learning design was adapted to the participants' lifestyles and tailored to the readiness of the nurse, ensuring a satisfactory e-learning user experience for the nurses.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors of Self-care Agency in Patients with Inflammatory Bowel Disease in Japan","authors":"Hikaru Mizuno, Mayu Katashima, Kayoko Sakagami, Yu Fujimoto, Chiyo Murauchi, Natsuko Seto","doi":"10.1159/000538007","DOIUrl":"https://doi.org/10.1159/000538007","url":null,"abstract":"Introduction: Currently, no self-care measurement tool specific to inflammatory bowel disease (IBD) exists in Japan. The Instrument for Diabetes Self-care Agency (IDSCA) is a reliable and valid self-care measurement tool for patients with diabetes. Factors affecting self-care ability assessed by IDSCA appear to meet the requirements for patients with IBD. Therefore, we created a self-care ability measurement tool adapted from IDSCA as an original draft for the Instrument for IBD Self-care Agency and extracted factors and items required to measure the self-care ability of patients with IBD. Methods: An anonymous questionnaire survey was distributed among 226 patients. Exploratory factor analysis examined the relationship of factors from multiple perspectives, identify factors based on their content, and confirm their internal consistency. Statistical analyses were performed using JMP🄬 14.0.0. Results: Five factors with 23 items were extracted from the IDSCA, including [Ability to build a human support system], [Ability to acquire knowledge], [Ability to maintain self-care], [Ability to self-manage], and [Ability to self-assess]. Cronbach’s alpha was 0.765–0.861 for each factor and 0.904 for the entire scale. Conclusion: We could identify the self-care agencies of patients with IBD, including 5 factors and 23 items. Focusing on these self-care factors may provide critical information to guide nurses’ self-care interventions.","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140371782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}